2024-516333-12-00
Recruiting
Phase 1
A First-in-Human clinical trial assessing safety of ES2B-C001 with or without Montanide in patients with HER2 expressing metastatic breast cancer.
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Expres2ion Biotechnologies ApS
- Enrollment
- 27
- Locations
- 1
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Thomas K. Jorgensen
Scientific
Expres2ion Biotechnologies ApS
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 2
A First in Human trial to study safety and tolerability of single rising intravitreal doses (oPen label, non-randomized, uncontrolled) and in Addition the early biological Response of mulTiple intravitreal doses (double-masked, RandomIzed, shamcontrolleD) of BI 765128 in panretinal photocoaGulation (PRP) treated diabetic rEtinopathy (DR) patients with diabetic macular ischemia (DMI) - the PARTRIDGE StudyDiabetic Macular IschemiaDMI10047061NL-OMON53613Boehringer Ingelheim1
Completed
Phase 1
A first-in-human study to evaluate the safety, tolerability and performance of uncoated and placebo-coated NanopatchesVaccination Delivery DeviceOther - Research that is not of generic health relevance and not applicable to specific health categories listed aboveACTRN12615000583549Vaxxas Pty Ltd18
Active, not recruiting
Not Applicable
CBPR277X2101Part 2: Atopic Dermatitis (AD)Part 3: Netherton Syndrome (NS)MedDRA version: 14.1Level: LLTClassification code 10003639Term: Atopic dermatitisSystem Organ Class: 100000004858MedDRA version: 14.1Level: PTClassification code 10062909Term: Netherton's syndromeSystem Organ Class: 10010331 - Congenital, familial and genetic disordersTherapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]EUCTR2011-000917-38-DEovartis Pharma Services AG85
Active, not recruiting
Not Applicable
CBPR277X2101EUCTR2011-000917-38-NLovartis Pharma Services AG85
Completed
Phase 2
A first-in-human study to evaluate safety and tolerability of repeated topical administrations of BPR277 ointment in healthy volunteers, and safety, tolerability, and preliminary efficacy of multiple topical administrations of BPR277 in patients with atopic dermatitis and Netherton syndrome (CBPR277X2101)Netherton syndrome10040790NL-OMON40034ovartis Pharma BV5